3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds

Core Viewpoint - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, presenting significant opportunities for companies like Viking Therapeutics, which is advancing its obesity treatment candidate VK2735 through clinical trials [4][2]. Group 1: Market Potential - The weight loss drug market is expected to grow substantially, with analysts predicting it will approach $100 billion by the end of the decade, indicating high demand and room for multiple companies to succeed [4]. - Demand for weight loss drugs has previously outstripped supply from major players like Eli Lilly and Novo Nordisk, suggesting that new entrants like Viking could capture market share as they deliver promising clinical results [5]. Group 2: Company Growth Potential - Viking Therapeutics has a current market value of approximately $3.5 billion, which allows for significant growth potential if it secures product approvals and generates revenue [8]. - A tenfold increase in market value could elevate Viking's market cap to $35 billion, contingent on the success of its product pipeline [8]. Group 3: Stock Performance and Investor Sentiment - Viking's stock experienced a notable surge of 121% following positive phase 2 trial data for VK2735, indicating strong investor interest and potential for future gains [10]. - Although the stock has since retraced some of its gains, the initial spike demonstrates that investors are closely monitoring Viking for any positive developments, which could lead to further stock appreciation [10][11].